Pharmacological and mechanistic aspects of quercetin in osteoporosis
Frontiers in Pharmacology · 25.01.2024 · 15
DOI: 10.3389/fphar.2024.1338951 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 25.01.2024. Verfasst von Ting-Ting Deng und 8 weiteren Autor:innen. Beteiligte Einrichtung: College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 175 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Osteoporosis (OP) is a bone disease associated with increasing age. Currently, the most common medications used to treat OP are anabolic agents, anti-resorptive agents, and medications with other mechanisms of action. However, many of these medications have unfavorable adverse effects or are not intended for long-term use, potentially exerting a severe negative impact on a patient’s life and career and placing a heavy burden on families and society. There is an urgent need to find new drugs that can replace these and have fewer adverse effects. Quercetin (Que) is a common flavonol in nature. Numerous studies have examined the therapeutic applications of Que. However, a comprehensive review of the anti-osteoporotic effects of Que has not yet been conducted. This review aimed to describe the recent studies on the anti-osteoporotic effects of Que, including its biological, pharmacological, pharmacokinetic, and toxicological properties. The outcomes demonstrated that Que could enhance OP by increasing osteoblast differentiation and activity and reducing osteoclast differentiation and activity via the pathways of Wnt/β-catenin, BMP/SMAD/RUNX2, OPG/RANKL/RANK, ERK/JNK, oxidative stress, apoptosis, and transcription factors. Thus, Que is a promising novel drug for the treatment of OP.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
- Shandong Institute of Endocrine and Metabolic Diseases, Jinan, China.
- Endocrine and Metabolic Diseases Hospital of Shandong First Medical University, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
- Bone Biomechanics Engineering Laboratory of Shandong Province, Shandong Medicinal Biotechnology Center, School of Biomedical Sciences, Neck-Shoulder and Lumbocrural Pain Hospital of Shandong First Medical University, Sh…
- NHC Key Laboratory of Biotechnology Drugs (Shandong Academy of Medical Sciences), Biomedical Sciences College, Shandong First Medical University, Jinan, China.
- Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China.
Zitieren
APA
Deng, T. T., Ding, W. Y., Lu, X. X., Zhang, Q. H., Du, J. X., Wang, L. J., Yang, M. N., Yin, Y., & Liu, F. J. (2024). Pharmacological and mechanistic aspects of quercetin in osteoporosis. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1338951
Vancouver
Deng TT, Ding WY, Lu XX, Zhang QH, Du JX, Wang LJ, et al. Pharmacological and mechanistic aspects of quercetin in osteoporosis. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1338951
BibTeX
@article{Deng2024,
author = {Deng, Ting-Ting and Ding, Wen-Yu and Lu, Xi-Xue and Zhang, Qing-Hao and Du, Jin-Xin and Wang, Li-Juan and Yang, Mei-Na and Yin, Ying and Liu, Fan-Jie},
title = {Pharmacological and mechanistic aspects of quercetin in osteoporosis},
journal = {Frontiers in Pharmacology},
year = {2024},
volume = {15},
doi = {10.3389/fphar.2024.1338951}
}
EUVIMED